Fonte: Fortune
The shot, paired with Merck's Keytruda, cut the risk of melanoma recurrence in a trial of more than 1,100 patients.
Ler na Fonte
Notícias Relacionadas
Lista de Notícias
Moderna’s and Merck’s personalized mRNA vaccine shows real promise against deadly skin cancer melanoma in late stage trial and sends stocks soaring
Moderna
Fortune
há 18h
